|
1) Robinson PF, Bristow MR. Beta blockers in Heart Failure, pharmacologic management. Feldman AM, editor. Blackwell: Futura; p.57-81
|
|
|
|
|
2) Bristow WF, Swedberg K, et al. Beneficial efforts of metoprolol in idiopathic dilated cardio-myopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342: 1441-6
|
|
|
|
|
3) MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001-6
|
|
|
|
|
|
4) Poole-Wilson PA, Swedberg K, Cleland JGF, et al; for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Results of the Carvedilol Or Metoprolol European Trial. Lancet. 2003; 362: 7-13
|
|
|
|
|
|
5) Bistow MR, Gilbert EM, Abraham WT, et al; for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failures. Circulation. 1996; 94: 2807-16
|
|
|
|
|
|
6) CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II(CIBIS-II): a randomized trial. Lancet. 1999; 353: 9-13
|
|
|
|
|
|
7) Simon T, Krause MM, Brentano CF, et al; on behalf of CIBIS II Investigators. Bisoprolol dose-response relationship in patients with congrestive heart failures: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J. 2003; 24: 552-9
|
|
|
|
|
|
8) Wikstrand J, Hjalmarson A, Waagstein F, et al. for the MERIT-HF Study Group, Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure, analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2002: 40: 491-8
|
|
|
|
|
|
9) Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of β-blocker therapy for patients with heart failure. Arch Intern Med. 2004; 104: 1389- 94
|
|
|
|
|
|
10) Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilo improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004: 147: 324-30
|
|
|
|
|
|
11) Okamoto H, Hori M, Yamazaki T, et al. On behalf of the J-CHF Investigators. Randomized trial to optimize the dose and efficacy of a beta-blocker in systolic heart failure: Japanese Chronic Heart Failure(J-CHF)Study. AHA 2009. 11. 17 Orland, USA
|
|
|
|
|